The impact of autologous bone marrow transplantation on hematopoietic recovery after high-dose cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with gynecological malignancies.
Twenty-six patients with gynecological malignancies (21 ovarian and 5 uterine malignant tumors) who were treated 42 times with high-dose cyclophosphamide, doxorubicin and cisplatin (CAP) chemotherapy with autologous bone marrow transplantation (ABMT) were assessed for the impact of predictive parameters on hematopoietic recovery. An inverse correlation was observed between the number of infused nucleated marrow cells (NMC)/kg or colony-forming units of granulocyte-macrophage (CFU-GM)/kg and the leukopenic duration < 1 x 10(3)/microliters; the correlation coefficients were r = -0.54 and -0.49, respectively (p < 0.001). The recovery time of platelet count to achieve more than 5 x 10(4)/microliters without transfusion was inversely correlated with CFU-GM/kg (r = -0.33, p < 0.05) but not with NMC/kg. Neither the episodes of fever nor the number of chemotherapy courses performed on the patients influenced the hematopoietic recovery. The numbers of infused CFU-GM and NMC were useful parameters of leukopoietic recovery after ABMT and high-dose CAP chemotherapy.
Murakami
M
M
Department of Obstetrics and Gynecology, School of Medicine, Tokai University, Kanagawa, Japan.
Shinozuka
T
T
Miyamoto
T
T
Fujii
A
A
Tokuda
Y
Y
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000628:therapy*; D006413:Hematopoietic System / Q000503:physiopathology*; D006801:Humans; D008875:Middle Aged
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin